Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5507622 | 0.83 | PTK2 (0.50) | ALDH1A1PTK2HDAC1HDAC6 | |
| SCHEMBL29690296 | 0.79 | ALDH1A1 (0.36) | ALDH1A1LMNACA12CA1CA2 | |
| SCHEMBL5513285 | 0.79 | ALDH1A1 (0.36) | ALDH1A1CA1CA2PTK2HDAC1 | |
| SCHEMBL13385877 | 0.79 | ALDH1A1 (0.36) | ALDH1A1PTK2 | |
| SCHEMBL30688718 | 0.79 | ALDH1A1 (0.36) | ALDH1A1CA1CA2PTK2HDAC1 | |
| SCHEMBL899953 | 0.79 | ALDH1A1 (0.36) | ALDH1A1LMNACA12CA1CA2 | |
| SCHEMBL1462129 | 0.79 | ALDH1A1 (0.36) | ALDH1A1LMNACA12CA1CA2 | |
| SCHEMBL31150397 | 0.77 | HSD17B1 (0.39) | ALDH1A1LMNACA12CA1CA2 | |
| SCHEMBL11589756 | 0.77 | HSD17B1 (0.39) | ALDH1A1LMNACA12CA1CA2 | |
| Hydrazine SCHEMBL27591097 | 0.76 | CA1 (0.46) | ALDH1A1LMNACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118183708-A | Method for preparing fluorocarbon material by using fluorine-containing polymer | 重庆大学锂电及新材料遂宁研究院 | 2024-06-14 | — | — | CN | claimed |
| CN-114349707-B | N-substituted urea compound and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2024-01-09 | — | — | CN | claimed |
| CN-103539942-B | A kind of preparation method of poly-2,3,5,6-tetrafluoroaniline nanostructure | Shanghai National Engineering Research Center for Nanotechnology Co., Ltd. (CN) | 2016-01-20 | — | — | CN | claimed |
| JP-2306945-A | — | — | None | — | — | JP | disclosed |
| JP-10182563-A | — | — | None | — | — | JP | disclosed |
| US-20260076918-A1 | HETEROTELECHELIC COMPOUNDS | KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION (JP) | 2026-03-19 | — | — | US | disclosed |
| EP-4688775-A1 | SUBSTITUTED SULTAM COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Avelos Therapeutics Inc. (KR) | 2026-02-11 | — | — | EP | disclosed |
| EP-4631948-A1 | NOVEL TRICYCLIC COMPOUND AS KRAS G12D INHIBITOR, AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2025-10-15 | — | — | EP | disclosed |
| US-12195473-B2 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2025-01-14 | — | — | US | disclosed |
| WO-2024205311-A1 | SUBSTITUTED SULTAM COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2024-10-03 | — | — | WO | disclosed |
| CN-115650925-B | Triazole alcohol derivative and preparation method and application thereof | 中国人民解放军海军军医大学 | 2024-09-24 | — | — | CN | disclosed |
| EP-0332033-A2 | N-cyclopropyl anilines and their use in processes for the synthesis of 1-cyclopropyl-quinolone-carboxylic acids and their derivatives | BAYER AG (DE) | 1989-09-13 | — | — | EP | disclosed |
| EP-0197280-B1 | BENZOYL UREAS | BAYER AG (DE) | 1989-06-07 | — | — | EP | disclosed |
| EP-0230053-A2 | 7-(Substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1987-07-29 | — | — | EP | disclosed |
| EP-0197280-A2 | Benzoyl ureas | BAYER AG (DE) | 1986-10-15 | — | — | EP | disclosed |
| US-4517130-A | Substituted amino acid process | ZOECON CORPORATION (US) | 1985-05-14 | — | — | US | disclosed |
| EP-0035084-B1 | SUBSTITUTED N-FLUORPHENYL-N'-HALOGEN BENZOYL UREAS, PROCESS FOR THEIR PREPRATION, COMPOSITIONS CONTAINING THEM AND THEIR USE IN COMBATING PESTS | CIBA-GEIGY AG (CH) | 1983-08-31 | — | — | EP | disclosed |
| EP-0053011-A1 | New herbicidal nicotinamide derivatives | MAY & BAKER LIMITED (GB) | 1982-06-02 | — | — | EP | disclosed |
| US-4310548-A | Pesticidal N-tetrafluorophenyl-N'-benzoyl ureas | CIBA-GEIGY CORPORATION (US) | 1982-01-12 | — | — | US | disclosed |
| EP-0035084-A1 | Substituted N-fluorphenyl-N'-halogen benzoyl ureas, process for their prepration, compositions containing them and their use in combating pests | CIBA-GEIGY AG (CH) | 1981-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076918-A1 | HETEROTELECHELIC COMPOUNDS | LDLR, MSR1, LPAR2 | ALDH1A1 2293/4885LMNA 1293/4885CA12 2655/4885 |
| US-12195473-B2 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | ALDH1A1 3978/4885LMNA 3922/4885CA12 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.